PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial
While the Phase III trial didn't meet the primary overall survival endpoint in PD-L1-positive patients, BMS will continue to track other endpoints.
NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC
The agency recommended that NHS England make the immunotherapy available based on data from the Phase III PACIFIC trial.
Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial
The SKYSCRAPER-01 trial of tiragolumab plus Tecentriq will continue to assess how the combination impacts PD-L1-positive advanced NSCLC patients' overall survival.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.